BAY 41-2272, a direct activator of soluble guanylate cyclase, reduces right ventricular hypertrophy and prevents pulmonary vascular remodeling during chronic hypoxia in neonatal rats.

@article{Deruelle2006BAY4A,
  title={BAY 41-2272, a direct activator of soluble guanylate cyclase, reduces right ventricular hypertrophy and prevents pulmonary vascular remodeling during chronic hypoxia in neonatal rats.},
  author={Philippe Deruelle and Vivek Balasubramaniam and Anette M. Kunig and Gregory J. Seedorf and Neil E. Markham and Steven H Abman},
  journal={Biology of the neonate},
  year={2006},
  volume={90 2},
  pages={
          135-44
        }
}
Exposure to hypoxia during the first weeks of life in newborn rats decreases vascular growth and alveolarization and causes pulmonary hypertension (PH). BAY 41-2272 is a novel direct activator of soluble guanylate cyclase independent of nitric oxide, effective as an acute pulmonary vasodilator in an animal model of persistent pulmonary hypertension of the newborn, but whether prolonged BAY 41-2272 therapy is effective in the setting of chronic PH is unknown. We hypothesize that BAY 41-2272… CONTINUE READING
BETA

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 31 CITATIONS

Effects of FHL1 and P21 on hypoxia-induced pulmonary vascular remodeling in neonatal rats

  • Experimental and therapeutic medicine
  • 2017
VIEW 4 EXCERPTS
CITES RESULTS & METHODS
HIGHLY INFLUENCED

Antenatal BAY 41-2272 reduces pulmonary hypertension in the rabbit model of congenital diaphragmatic hernia.

  • American journal of physiology. Lung cellular and molecular physiology
  • 2016
VIEW 2 EXCERPTS
CITES RESULTS & BACKGROUND